title: Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial.
abstract: OBJECTIVE
  Two studies have reported on the superiority of a proton pump inhibitor (PPI) compared with a histamine-2-receptor antagonist for the treatment of artificial ulcers after endoscopic submucosal dissection (ESD), but the optimal dose of PPI remains to be defined. The aim of this study was to evaluate the possibility of reducing the dose of PPI. The authors thus compared 30 mg (standard-dose) and 15 mg (half-dose) lansoprazole in terms of ulcer healing, prevention of bleeding and quality of life.
  
  
  METHODS
  91 patients with gastric mucosal neoplasm were enrolled. All patients who underwent ESD were administered lansoprazole 30 mg daily during the first week, after which they were randomly assigned to either the standard-dose or half-dose group.
  
  
  RESULTS
  One patient in each group developed hematemesis. The stage of ulcers, ulcer reduction ratios and scores on the Gastrointestinal Symptom Rating Scale did not differ at 28 and 56 days. The costs of PPI for the half-dose group and standard-dose group were 7,326.5 and 11,698.4 JPY, respectively, i.e. a difference of 471.9 JPY.
  
  
  CONCLUSIONS
  A reduced dose of PPI after 1 week of ESD was equivalent in treatment performance to the standard dose and cheaper.
authors.affiliation: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Kawano
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Kawahara
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hori
authors.forename: Daisuke
authors.initials: D
authors.lastname: Tanioka
authors.forename: Takao
authors.initials: T
authors.lastname: Tsuzuki
authors.forename: Masafumi
authors.initials: M
authors.lastname: Inoue
authors.forename: Satoru
authors.initials: S
authors.lastname: Yagi
authors.forename: Ryuta
authors.initials: R
authors.lastname: Takenaka
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000191:economics; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics; D003362:Cost-Benefit Analysis; D005260:Female; D005753:Gastric Mucosa / Q000601:surgery; D005773:Gastroscopy; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D010438:Peptic Ulcer Hemorrhage / Q000517:prevention & control; D011182:Postoperative Care; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000191:economics; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000601:surgery; D013276:Stomach Ulcer / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole